• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

视网膜母细胞瘤中检测MYCN扩增的参数和阈值的定义。

Definition of parameters and thresholds to detect MYCN amplification in retinoblastomas.

作者信息

Bielefeld C, Hugo T, Sievers N, Ketteler P, Biewald E, Kiefer T, Papaioannou K, Tüller P, Ryl T, Busch M, Rawitzer J, Schildhaus H-U, Ting S

机构信息

Reference Pathology for Pediatric Eye Tumors, Kassel, Germany.

Institute of Pathology Nordhessen, Germaniastrasse 7, 34119, Kassel, Germany.

出版信息

Virchows Arch. 2025 Aug 21. doi: 10.1007/s00428-025-04219-x.

DOI:10.1007/s00428-025-04219-x
PMID:40839307
Abstract

Retinoblastoma is a malignant childhood neoplasm where MYCN amplification defines a subset of tumors with worse prognosis. FISH (fluorescence in situ hybridization) represents a fast and reliable method to measure gene copy numbers in various tumors but has not yet been systematically evaluated in retinoblastoma. In this study, we define criteria for FISH detection of MYCN amplification in a systematic unbiased approach by using a well characterized series of 44 clinical retinoblastoma samples. We (i) determined potential measurements and parameters by a comprehensive literature review, (ii) analyzed a retrospective cohort of samples with known MYCN amplification, (iii) determined statistically measurements and cut-offs, which allow reliable detection of amplified tumors, and (iv) applied these criteria to a prospective cohort. We demonstrate that average gene copy number (AVGCN) of MYCN/cell, MYCN/CEN2 ratio, and MYCN-CEN2 difference reveal the lowest statistical variance in amplified samples, if at least 50 cells were counted. The combination of these three parameters and cut-offs, namely AVGCN ≥ 10, MYCN/CEN2 ratio ≥ 3, and MYCN-CEN2 difference ≥ 8, allowed a reliable distinction between amplified and non-amplified cases. The prevalence of MYCN-amplified cases was 4/33 (12.1%) among prospective clinical samples indicating a higher percentage of positive tumors than previously reported. Our data provide the first evidence for well-grounded MYCN FISH criteria in retinoblastoma.

摘要

视网膜母细胞瘤是一种儿童恶性肿瘤,其中MYCN基因扩增定义了一组预后较差的肿瘤。荧光原位杂交(FISH)是一种快速可靠的方法,可用于测量各种肿瘤中的基因拷贝数,但尚未在视网膜母细胞瘤中进行系统评估。在本研究中,我们通过使用44例具有明确特征的临床视网膜母细胞瘤样本,以系统无偏倚的方法定义了FISH检测MYCN基因扩增的标准。我们(i)通过全面的文献综述确定了潜在的测量方法和参数,(ii)分析了一组已知MYCN基因扩增的回顾性样本队列,(iii)确定了统计学测量方法和临界值,以实现对扩增肿瘤的可靠检测,(iv)将这些标准应用于前瞻性队列。我们证明,如果至少计数50个细胞,MYCN/细胞的平均基因拷贝数(AVGCN)、MYCN/CEN2比值和MYCN-CEN2差异在扩增样本中显示出最低的统计方差。这三个参数和临界值的组合,即AVGCN≥10、MYCN/CEN2比值≥3和MYCN-CEN2差异≥8,能够可靠地区分扩增和未扩增病例。在前瞻性临床样本中,MYCN扩增病例的患病率为4/33(12.1%),表明阳性肿瘤的比例高于先前报道。我们的数据为视网膜母细胞瘤中基于充分证据的MYCN FISH标准提供了首个证据。

相似文献

1
Definition of parameters and thresholds to detect MYCN amplification in retinoblastomas.视网膜母细胞瘤中检测MYCN扩增的参数和阈值的定义。
Virchows Arch. 2025 Aug 21. doi: 10.1007/s00428-025-04219-x.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
4
Retinoblastoma with MYCN Amplification Diagnosed from Cell-Free DNA in the Aqueous Humor.通过房水游离DNA诊断出的伴有MYCN扩增的视网膜母细胞瘤。
Ocul Oncol Pathol. 2024 Apr;10(1):15-24. doi: 10.1159/000533311. Epub 2023 Aug 25.
5
MYCN amplification defines an aggressive phenotype in IDH-mutant gliomas.MYCN基因扩增在异柠檬酸脱氢酶(IDH)突变型胶质瘤中表现出侵袭性表型。
J Pathol Clin Res. 2025 Sep;11(5):e70045. doi: 10.1002/2056-4538.70045.
6
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
7
Genetic determinants of testicular sperm extraction outcomes: insights from a large multicentre study of men with non-obstructive azoospermia.睾丸精子提取结果的遗传决定因素:来自一项针对非梗阻性无精子症男性的大型多中心研究的见解
Hum Reprod Open. 2025 Aug 29;2025(3):hoaf049. doi: 10.1093/hropen/hoaf049. eCollection 2025.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.

本文引用的文献

1
Retinoblastoma with and without Extraocular Tumor Extension: A Global Comparative Study of 3435 Patients.伴有和不伴有眼外肿瘤扩展的视网膜母细胞瘤:3435例患者的全球比较研究
Ophthalmol Sci. 2024 Oct 30;5(2):100637. doi: 10.1016/j.xops.2024.100637. eCollection 2025 Mar-Apr.
2
Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case-control study.基于 MRI 的放射组学鉴别 MYCN 扩增 RB1 野生型视网膜母细胞瘤与双等位基因突变 RB1 型视网膜母细胞瘤:一项回顾性多中心病例对照研究。
Sci Rep. 2024 Oct 23;14(1):25103. doi: 10.1038/s41598-024-76933-6.
3
A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma.
一种由 MYCN 驱动的去分化特征确定了一组侵袭性视网膜母细胞瘤亚群。
Commun Biol. 2024 Jul 30;7(1):919. doi: 10.1038/s42003-024-06596-6.
4
Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.IDH 突变型胶质瘤的基因组特征:MYCN 扩增型 IDH 突变型星形细胞瘤预后最差。
Sci Rep. 2023 Apr 25;13(1):6761. doi: 10.1038/s41598-023-32153-y.
5
Long-Term Results after Intraocular Surgery in Treated Retinoblastoma Eyes.视网膜母细胞瘤治疗眼内手术后的长期结果
Ocul Oncol Pathol. 2022 Nov;8(3):161-167. doi: 10.1159/000524610. Epub 2022 Apr 20.
6
High-Level Amplified Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures.高水平扩增的高侵袭性视网膜母细胞瘤肿瘤保留独特分子特征。
Ophthalmol Sci. 2022 Jun 20;2(3):100188. doi: 10.1016/j.xops.2022.100188. eCollection 2022 Sep.
7
Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas.小儿 IDH 野生型、H3 野生型半球胶质瘤的分子图谱。
Lab Invest. 2022 Jul;102(7):731-740. doi: 10.1038/s41374-022-00769-9. Epub 2022 Mar 24.
8
Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study.用于预测髓母细胞瘤MYCN扩增及分子分型的单nCounter检测:一项多中心研究
J Neurooncol. 2022 Mar;157(1):27-35. doi: 10.1007/s11060-022-03965-1. Epub 2022 Feb 15.
9
A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression.一种具有干性特征、去分化的锥形状态和神经元/神经节细胞基因表达的高危视网膜母细胞瘤亚型。
Nat Commun. 2021 Sep 22;12(1):5578. doi: 10.1038/s41467-021-25792-0.
10
Incidence of Retinoblastoma Has Increased: Results from 40 European Countries.视网膜母细胞瘤发病率上升:来自40个欧洲国家的结果
Ophthalmology. 2021 Sep;128(9):1369-1371. doi: 10.1016/j.ophtha.2021.01.024. Epub 2021 Jan 26.